Thibault de La Motte Rouge, MD

Centre Eugene Marquis · Centre Eugène Marquis, Rennes

Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.

Registry trials as an overall official

all conditions, ClinicalTrials.gov

NIH grants tied to them

NIH RePORTER

Trial papers in breast cancer

PubMed author-name match

Trials

Studies that name Thibault de La Motte Rouge, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 13:58 UTC. Open this list on ClinicalTrials.gov

Ph2
NCT06450314 · Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.
UNICANCER · recruiting · Metastatic Breast Cancer, HER2-positive Breast Cancer · principal investigator
Ph2
NCT05296746 · Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer
SOLTI Breast Cancer Research Group · active not recruiting · Breast Cancer Stage II · principal investigator
N/A
NCT04027868 · Genomic BRCA and Extensive ovArian Cancer Testing
ARCAGY/ GINECO GROUP · completed · Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 13:58 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

Most cited trial papers

PubMed returned no clinical-trial papers for this author name in breast cancer.